checkAd

    EQS-News  161  0 Kommentare DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE - Seite 2

     

    "AccuTOX is an amazing molecule! AccuTOX has the capacity to trigger cancer cell death when used as a direct cancer injectable, and AccuTOX, the same molecule, converts MSCs into potent antigen presenting cells capable of priming potent anti-tumoral responses using a 10-fold lower antigen preparation" says Mr. Plouffe, Chief Executive Officer of Defence Therapeutics.

     

    The ARM-002TM vaccine was tested in vivo in the context of melanoma. The vaccine elicited an impressive anti-tumoral response, which prompt the team to widen its scope of application by further testing it on "hard to treat" ovarian and pancreatic cancers. The Defence team are conducting additional studies in parallel to decipher the exact mode of action of AccuTOX in reprograming MSCs while studying the mechanistic behind the ARM-002TM potency using different in vivo studies. Once these studies finalized and the "Dry Run" manufacturing of the ARM-002TM vaccine completed, a request to obtain clearance for a Phase I trial targeting a basket of solid tumors will be initiated.

     

    Data Bridge Market Research analyses that the solid tumours market was valued at $209.61-billion (U.S.) in 2021 and is expected to reach $901.27-billion (U.S.) by 2029, registering a CAGR (compound annual growth rate) of 20 per cent during the forecast period of 2022 to 2029.

    https://www.databridgemarketresearch.com/reports/global-solid-tumors-market#:~:text=Data%20Bridge%20Market%20Research%20analyses,period%20of%202022%20to%202029.

     

    About Defence:

    Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

    Seite 2 von 4


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE - Seite 2 EQS-News: Defence Therapeutics Inc. / Key word(s): Product Launch DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE 26.03.2024 / 08:00 CET/CEST The issuer is …

    Schreibe Deinen Kommentar

    Disclaimer